- call +1-201-465-4211
- email sales@mrinsights.biz
Mucopolysaccharidosis consists of a group of more than 40 genetic disorders that forms a part of lysosomal storage disease. They are caused by an inherited deficiency of an enzyme involved in the degradation of acid glycosaminoglycans (GAGs), which was previously known as mucopolysaccharidosis. All of the mucopolysaccharidoses are rare, autosomal recessive, except for mucopolysaccharidosis III, as it is X-linked.
Scope of the Report:
This report studies the Gene Therapy for Mucopolysaccharidosis market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Gene Therapy for Mucopolysaccharidosis market by product type and applications/end industries.
Over the past few years, gene therapy has emerged as one of the most exciting approaches for the treatment of mucopolysaccharidosis. One of the promising therapy is replacement gene therapy, which replaces faulty genes with normal ones in the body. It is considered to be a potential cure to mucopolysaccharidoses and a promising option in the long run.
The global Gene Therapy for Mucopolysaccharidosis market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Gene Therapy for Mucopolysaccharidosis.
Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.
Market Segment by Companies, this report covers
Sangamo Therapeutics
Swedish Orphan Biovitrum
uniQure
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Intravenous
ICV
Intracerebral
Intracisternal
Market Segment by Applications, can be divided into
Mucopolysaccharidosis I
Mucopolysaccharidosis II
Mucopolysaccharidosis III A
Mucopolysaccharidosis III B
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Gene Therapy for Mucopolysaccharidosis Market Overview
1.1 Product Overview and Scope of Gene Therapy for Mucopolysaccharidosis
1.2 Classification of Gene Therapy for Mucopolysaccharidosis by Types
1.2.1 Global Gene Therapy for Mucopolysaccharidosis Revenue Comparison by Types (2017-2023)
1.2.2 Global Gene Therapy for Mucopolysaccharidosis Revenue Market Share by Types in 2017
1.2.3 Intravenous
1.2.4 ICV
1.2.5 Intracerebral
1.2.6 Intracisternal
1.3 Global Gene Therapy for Mucopolysaccharidosis Market by Application
1.3.1 Global Gene Therapy for Mucopolysaccharidosis Market Size and Market Share Comparison by Applications (2013-2023)
1.3.2 Mucopolysaccharidosis I
1.3.3 Mucopolysaccharidosis II
1.3.4 Mucopolysaccharidosis III A
1.3.5 Mucopolysaccharidosis III B
1.4 Global Gene Therapy for Mucopolysaccharidosis Market by Regions
1.4.1 Global Gene Therapy for Mucopolysaccharidosis Market Size (Million USD) Comparison by Regions (2013-2023)
1.4.1 North America (USA, Canada and Mexico) Gene Therapy for Mucopolysaccharidosis Status and Prospect (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy) Gene Therapy for Mucopolysaccharidosis Status and Prospect (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Gene Therapy for Mucopolysaccharidosis Status and Prospect (2013-2023)
1.4.4 South America (Brazil, Argentina, Colombia) Gene Therapy for Mucopolysaccharidosis Status and Prospect (2013-2023)
1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Gene Therapy for Mucopolysaccharidosis Status and Prospect (2013-2023)
1.5 Global Market Size of Gene Therapy for Mucopolysaccharidosis (2013-2023)
2 Manufacturers Profiles
2.1 Sangamo Therapeutics
2.1.1 Business Overview
2.1.2 Gene Therapy for Mucopolysaccharidosis Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Sangamo Therapeutics Gene Therapy for Mucopolysaccharidosis Revenue, Gross Margin and Market Share (2016-2017)
2.2 Swedish Orphan Biovitrum
2.2.1 Business Overview
2.2.2 Gene Therapy for Mucopolysaccharidosis Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Swedish Orphan Biovitrum Gene Therapy for Mucopolysaccharidosis Revenue, Gross Margin and Market Share (2016-2017)
2.3 uniQure
2.3.1 Business Overview
2.3.2 Gene Therapy for Mucopolysaccharidosis Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 uniQure Gene Therapy for Mucopolysaccharidosis Revenue, Gross Margin and Market Share (2016-2017)
3 Global Gene Therapy for Mucopolysaccharidosis Market Competition, by Players
3.1 Global Gene Therapy for Mucopolysaccharidosis Revenue and Share by Players (2013-2018)
3.2 Market Concentration Rate
3.2.1 Top 5 Gene Therapy for Mucopolysaccharidosis Players Market Share
3.2.2 Top 10 Gene Therapy for Mucopolysaccharidosis Players Market Share
3.3 Market Competition Trend
4 Global Gene Therapy for Mucopolysaccharidosis Market Size by Regions
4.1 Global Gene Therapy for Mucopolysaccharidosis Revenue and Market Share by Regions
4.2 North America Gene Therapy for Mucopolysaccharidosis Revenue and Growth Rate (2013-2018)
4.3 Europe Gene Therapy for Mucopolysaccharidosis Revenue and Growth Rate (2013-2018)
4.4 Asia-Pacific Gene Therapy for Mucopolysaccharidosis Revenue and Growth Rate (2013-2018)
4.5 South America Gene Therapy for Mucopolysaccharidosis Revenue and Growth Rate (2013-2018)
4.6 Middle East and Africa Gene Therapy for Mucopolysaccharidosis Revenue and Growth Rate (2013-2018)
5 North America Gene Therapy for Mucopolysaccharidosis Revenue by Countries
5.1 North America Gene Therapy for Mucopolysaccharidosis Revenue by Countries (2013-2018)
5.2 USA Gene Therapy for Mucopolysaccharidosis Revenue and Growth Rate (2013-2018)
5.3 Canada Gene Therapy for Mucopolysaccharidosis Revenue and Growth Rate (2013-2018)
5.4 Mexico Gene Therapy for Mucopolysaccharidosis Revenue and Growth Rate (2013-2018)
6 Europe Gene Therapy for Mucopolysaccharidosis Revenue by Countries
6.1 Europe Gene Therapy for Mucopolysaccharidosis Revenue by Countries (2013-2018)
6.2 Germany Gene Therapy for Mucopolysaccharidosis Revenue and Growth Rate (2013-2018)
6.3 UK Gene Therapy for Mucopolysaccharidosis Revenue and Growth Rate (2013-2018)
6.4 France Gene Therapy for Mucopolysaccharidosis Revenue and Growth Rate (2013-2018)
6.5 Russia Gene Therapy for Mucopolysaccharidosis Revenue and Growth Rate (2013-2018)
6.6 Italy Gene Therapy for Mucopolysaccharidosis Revenue and Growth Rate (2013-2018)
7 Asia-Pacific Gene Therapy for Mucopolysaccharidosis Revenue by Countries
7.1 Asia-Pacific Gene Therapy for Mucopolysaccharidosis Revenue by Countries (2013-2018)
7.2 China Gene Therapy for Mucopolysaccharidosis Revenue and Growth Rate (2013-2018)
7.3 Japan Gene Therapy for Mucopolysaccharidosis Revenue and Growth Rate (2013-2018)
7.4 Korea Gene Therapy for Mucopolysaccharidosis Revenue and Growth Rate (2013-2018)
7.5 India Gene Therapy for Mucopolysaccharidosis Revenue and Growth Rate (2013-2018)
7.6 Southeast Asia Gene Therapy for Mucopolysaccharidosis Revenue and Growth Rate (2013-2018)
8 South America Gene Therapy for Mucopolysaccharidosis Revenue by Countries
8.1 South America Gene Therapy for Mucopolysaccharidosis Revenue by Countries (2013-2018)
8.2 Brazil Gene Therapy for Mucopolysaccharidosis Revenue and Growth Rate (2013-2018)
8.3 Argentina Gene Therapy for Mucopolysaccharidosis Revenue and Growth Rate (2013-2018)
8.4 Colombia Gene Therapy for Mucopolysaccharidosis Revenue and Growth Rate (2013-2018)
9 Middle East and Africa Revenue Gene Therapy for Mucopolysaccharidosis by Countries
9.1 Middle East and Africa Gene Therapy for Mucopolysaccharidosis Revenue by Countries (2013-2018)
9.2 Saudi Arabia Gene Therapy for Mucopolysaccharidosis Revenue and Growth Rate (2013-2018)
9.3 UAE Gene Therapy for Mucopolysaccharidosis Revenue and Growth Rate (2013-2018)
9.4 Egypt Gene Therapy for Mucopolysaccharidosis Revenue and Growth Rate (2013-2018)
9.5 Nigeria Gene Therapy for Mucopolysaccharidosis Revenue and Growth Rate (2013-2018)
9.6 South Africa Gene Therapy for Mucopolysaccharidosis Revenue and Growth Rate (2013-2018)
10 Global Gene Therapy for Mucopolysaccharidosis Market Segment by Type
10.1 Global Gene Therapy for Mucopolysaccharidosis Revenue and Market Share by Type (2013-2018)
10.2 Global Gene Therapy for Mucopolysaccharidosis Market Forecast by Type (2018-2023)
10.3 Intravenous Revenue Growth Rate (2013-2023)
10.4 ICV Revenue Growth Rate (2013-2023)
10.5 Intracerebral Revenue Growth Rate (2013-2023)
10.6 Intracisternal Revenue Growth Rate (2013-2023)
11 Global Gene Therapy for Mucopolysaccharidosis Market Segment by Application
11.1 Global Gene Therapy for Mucopolysaccharidosis Revenue Market Share by Application (2013-2018)
11.2 Gene Therapy for Mucopolysaccharidosis Market Forecast by Application (2018-2023)
11.3 Mucopolysaccharidosis I Revenue Growth (2013-2018)
11.4 Mucopolysaccharidosis II Revenue Growth (2013-2018)
11.5 Mucopolysaccharidosis III A Revenue Growth (2013-2018)
11.6 Mucopolysaccharidosis III B Revenue Growth (2013-2018)
12 Global Gene Therapy for Mucopolysaccharidosis Market Size Forecast (2018-2023)
12.1 Global Gene Therapy for Mucopolysaccharidosis Market Size Forecast (2018-2023)
12.2 Global Gene Therapy for Mucopolysaccharidosis Market Forecast by Regions (2018-2023)
12.3 North America Gene Therapy for Mucopolysaccharidosis Revenue Market Forecast (2018-2023)
12.4 Europe Gene Therapy for Mucopolysaccharidosis Revenue Market Forecast (2018-2023)
12.5 Asia-Pacific Gene Therapy for Mucopolysaccharidosis Revenue Market Forecast (2018-2023)
12.6 South America Gene Therapy for Mucopolysaccharidosis Revenue Market Forecast (2018-2023)
12.7 Middle East and Africa Gene Therapy for Mucopolysaccharidosis Revenue Market Forecast (2018-2023)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
List of Tables and Figures
Figure Gene Therapy for Mucopolysaccharidosis Picture
Table Product Specifications of Gene Therapy for Mucopolysaccharidosis
Table Global Gene Therapy for Mucopolysaccharid
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
